Citius Pharmaceuticals Inc. Common Stock Prediction
AI-powered sentiment analysis and prediction trends for CTXR, updated each market day.
CTXR AI Sentiment
AI predicts Citius Pharmaceuticals Inc. Common stock is likely to increase over the next 10 market days.
Prediction date: Sept. 17, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Citius Pharmaceuticals Inc. Common
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
Sector
Exchange
Market Cap
$16,139,365
Cap Tier
Employees
23
Headquarters
CRANFORD, NJ
Listed Since
Oct. 18, 2011
Website
CTXR Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CTXR Volatility
Citius Pharmaceuticals Inc. Common has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
